ArticleVascular medicine (London, England)2023
Medical therapies, comorbid conditions, and functional performance in people with peripheral artery disease enrolled in clinical trials between 2004 and 2021.
Pooja Nayak, Tamar Polonsky, Lu Tian, Philip Greenland, Shujun Xu, Dongxue Zhang, Lihui Zhao, Michael H Criqui, Melina R Kibbe, Barbara Gladders and 4 more
Open access · greenAbstract readLetter
In one paragraphArticle in Vascular medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors at 8 institutions in 1 country.
Pooja NayakDepartment of Medicine, University of Illinois Chicago, Chicago, IL, USA.
Tamar PolonskyUniversity of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Lu TianDepartment of Health Research and Policy, Stanford University, Stanford, CA, USA.
Philip GreenlandNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Shujun XuNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Dongxue ZhangNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lihui ZhaoNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Michael H CriquiDepartment of Family Medicine and Public Health, University of California San Diego, San Diego, CA, USA.
Barbara GladdersDartmouth School of Medicine, Hanover, NH, USA.
Philip GoodneyDartmouth School of Medicine, Hanover, NH, USA.
Jack M GuralnikDepartment of Epidemiology, University of Maryland, College Park, MD, USA.
Northwestern University · USDartmouth College · USStanford University · USUniversity of California San Diego · USUniversity of Chicago · USUniversity of Illinois Chicago · USUniversity of Maryland, College Park · USUniversity of Virginia · US
Funding
PROgenitor Cell Release Plus Exercise To Improve Functional Performance In PADR01HL107510 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2011 to 2015
$5.6MImproving Functioning in Peripheral Arterial DiseaseR01HL073351 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2003 to 2007
$4.9MTELmisartan plus EXercise to improve functioning in PAD: The TELEX TrialR01HL126117 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2015 to 2019
$3.7MImprove PAD PERformance with METformin. The PERMET TrialR01HL131771 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2017 to 2021
$3.7MCOCOA PAD II Trial: Microbiome Ancillary StudyR01AG068458 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2021 to 2025
$3.4MINTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE TrialR01AG057693 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2018 to 2022
$3.2MLow InTensity Exercise Intervention for Peripheral Artery Disease: The LITE TrialR01HL122846 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2015 to 2018
$3.0MIncreasing Activity in Peripheral Arterial DiseaseR01HL088589 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2008 to 2011
$2.9MSupplement to Epicatechin-rich COCOA to improve walking performance in PAD: the COCOA-PAD-S StudyR21AG050897 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2016 to 2017
$615kSupplement to RESveratrol To Improve Outcomes in oldeR pEople with PAD (the RESTORE-S Trial)R21AG047510 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2014 to 2015
$533kUnacylated Ghrelin to Improve FuncTioning in PAD: the GIFT TrialR21AG063076 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2019 to 2020
$457kHepatocyte growth factor to Improve Functioning in PAD: the HI-PAD StudyR21AG056903 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2017 to 2018
$388kNHLBI NIH HHS R01 HL073351NHLBI NIH HHS R01 HL088589NHLBI NIH HHS R01 HL107510NHLBI NIH HHS R01 HL122846NHLBI NIH HHS R01 HL126117NHLBI NIH HHS R01 HL131771NIA NIH HHS R01 AG057693NIA NIH HHS R01 AG068458NIA NIH HHS R21 AG047510NIA NIH HHS R21 AG050897NIA NIH HHS R21 AG056903NIA NIH HHS R21 AG063076
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Peripheral Arterial DiseaseExercise TherapyHumansIntermittent ClaudicationPhysical Functional PerformanceWalkingexercisefunctional assessmentintermittent claudicationopioidsperipheral artery disease (PAD)randomized controlled trial (RCT)statins
Identifiers
PMID36588397
PMCPMC11663016
OpenAlexW4313388125
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390